ArticleBMC medical imaging2026
Incidence, timing, and risk factors of severe complications after percutaneous ultrasound-guided tumor biopsy: a proposal for safe aftercare based on 30 years´ experience.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPercutaneous ultrasound (US)-guided core-needle biopsies (CNBs) is increasingly used to obtain tumor tissue across all anatomic regions to guide personalized cancer treatment; however, data with particular attention on serious adverse events (SAEs) and appropriate observation times to detect clinically-relevant SAEs are limited. We aimed to assess the incidence, influencing factors, and temporal manifestation of SAEs after US-guided CNB of tumors in the thorax and abdomen to identify patient safety measures with a focus on observation time that will allow safe post-biopsy patient discharge.
methodsThis retrospective review of a prospectively collected single-institutional database included 7.494 patients who underwent percutaneous US-guided automated CNBs of 522 thoracic and 6.972 abdominal tumors between 1992 and 2022. The database was reviewed to identify biopsy-related SAEs of Clavien-Dindo (CD) grade ≥ 2, which were classified as acute (< 6 h), subacute (6-24 h), or delayed (> 24 h). CD and CIRSE ≥ 2 scales were compared for counting biopsy-related SAEs.
resultsAmong a total of 29 (0.39%) SAEs CD grade ≥ 2, 28% (8/29) were acute, 62% (18/29) subacute, 10% (3/29) delayed, 90% (26/29) bleeding-related, and 10% (3/29) pneumothorax-related. Treatments were erythrocyte transfusion (12x), surgical bleeding control (10x), transarterial coiling (4x), and chest tube placement (3x). Incidences of ≥ 1% were observed for bleeding after spleen (1.6%) and kidney (1.3%) biopsy (other sites: 0-0.4%) and for pneumothorax after transpleural biopsy (1.6%) of intrapulmonal nodules. Bleeding risk associated significantly with INR, number of needle passes, double antiplatelet medication, and, in liver biopsy, with a hypervascular tumor type (p < 0.05). CIRSE classification added 7 prolonged observational stays without treatment (CIRSE grade 2/3), raising the SAE rate from 0.39% to 0.48%. No patient death occurred.
conclusionsOur results support the safety of the procedure but also highlight potential risks. SAE incidences vary by biopsy site and site-independent factors, and most SAEs occur within 6-24-hours after biopsy, suggesting need for risk-adjusted observation times, either for < 6-hours or 24-hours, to allow safe patient discharge. Further prospective studies are needed to validate our findings and to define reasonable thresholds for low and high SAE risks that could tailor aftercare time in a pragmatic and clinically-relevant sense. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.